Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- M&A Inevitable for Japanese Drug Companies: Nikko Solomon's Analyst
September 24, 2001
- FY2001 Korosho White Paper Stresses Importance of Social Security as Safety Net
September 24, 2001
- 9 Active Ingredients to Be Approved in September
September 24, 2001
- PMSB to Take Measures to Ensure Quality of Imported Medical Devices
September 24, 2001
- REGULATORY NEWS IN BRIEF
September 24, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 24, 2001
- Taisho, Tanabe Agree to Integrate Their Business
September 24, 2001
- GEYMS Launches New Multislice CT "LightSpeed Ultra" in Japan First
September 24, 2001
- DIAGNOSTIC NEWS IN BRIEF
September 24, 2001
- Terumo Takes Over Home Oxygen Business from Sumitomo Bakelite
September 24, 2001
- Sankyo to Give Greater Importance to Clinic Market for Life-style Diseases
September 24, 2001
- Takara Launches Nexell's Magnetic Cell Separation System from Nexell
September 24, 2001
- 51% of JPMA Member Firms Have Documented Compliance Programs
September 24, 2001
- Makers Outsource More OTC Drug Marketing Activities
September 24, 2001
- FJPWA Decides to Cooperate in Market Price Survey
September 24, 2001
- OTC NEWS IN BRIEF
September 24, 2001
- Wholesalers' Bargaining Ability to Be Tested in 2002
September 24, 2001
- WORLD NEWS IN BRIEF
September 24, 2001
- BUSINESS NEWS IN BRIEF -1-
September 24, 2001
- P450 DB Provides Valuable Information on Drug Interactions: FQS, Shionogi
September 24, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…